Martha Sajatovic1,2,3, Jennifer B Levin1,2, Johnny Sams1,2, Kristin A Cassidy1, Kouri Akagi1, Michelle E Aebi2, Luis F Ramirez1, Steven A Safren4, Curtis Tatsuoka2,3. 1. Department of Psychiatry, Case Western Reserve University School of Medicine, Cleveland, OH, USA. 2. University Hospitals Case Medical Center, Neurological and Behavioral Outcomes Center, Cleveland, OH, USA. 3. Department of Neurology, Case Western Reserve University School of Medicine, Cleveland, OH, USA. 4. Department of Psychiatry, Harvard Medical School/Massachusetts General Hospital, Boston, MA, USA.
Abstract
OBJECTIVES: This analysis of screening and baseline data from an ongoing trial examined self-report versus automated adherence monitoring and assessed the relationship between bipolar disorder (BD) symptoms and adherence in 104 poorly adherent individuals. METHODS: Adherence was measured with the Tablets Routine Questionnaire (TRQ) and the Medication Event Monitoring System (MEMS). Symptoms were measured with the Montgomery-Åsberg Depression Rating Scale (MADRS), the Young Mania Rating Scale (YMRS), and the Brief Psychiatric Rating Scale (BPRS). RESULTS: The mean age of the sample was 46.3 years [standard deviation (SD) = 9.41 years], with 72% (n = 75) women and 71% (n = 74) African American subjects. Adherence improved from screening to baseline, with a mean missed drug proportion measured by TRQ of 61.43% (SD = 26.48%) versus a baseline mean of 46.61% (SD = 30.55%). The mean proportion of missed medication using MEMS at baseline was 66.43% (SD = 30.40%). The correlation between TRQ and MEMS was 0.47. The correlation between a single index drug and all BD medications was 0.95. Symptoms were generally positively correlated with TRQ (worse adherence = more severe symptoms), but in most instances was only at a trend level (p > 0.05), with the exception of the correlations between baseline TRQ and MADRS and BPRS, which were positive (r = 0.20 and r = 0.21, respectively) and significant (p ≤ 0.05). CONCLUSIONS: In patients with BD, monitoring increased adherence by 15%. MEMS identified 20% more non-adherence than self-report. Using a standard procedure to identify a single index drug for adherence monitoring may be one way to assess global adherence in patients with BD receiving polypharmacy treatment. Greater BD symptom severity may be a clinical indicator to assess for adherence problems.
OBJECTIVES: This analysis of screening and baseline data from an ongoing trial examined self-report versus automated adherence monitoring and assessed the relationship between bipolar disorder (BD) symptoms and adherence in 104 poorly adherent individuals. METHODS: Adherence was measured with the Tablets Routine Questionnaire (TRQ) and the Medication Event Monitoring System (MEMS). Symptoms were measured with the Montgomery-Åsberg Depression Rating Scale (MADRS), the Young Mania Rating Scale (YMRS), and the Brief Psychiatric Rating Scale (BPRS). RESULTS: The mean age of the sample was 46.3 years [standard deviation (SD) = 9.41 years], with 72% (n = 75) women and 71% (n = 74) African American subjects. Adherence improved from screening to baseline, with a mean missed drug proportion measured by TRQ of 61.43% (SD = 26.48%) versus a baseline mean of 46.61% (SD = 30.55%). The mean proportion of missed medication using MEMS at baseline was 66.43% (SD = 30.40%). The correlation between TRQ and MEMS was 0.47. The correlation between a single index drug and all BD medications was 0.95. Symptoms were generally positively correlated with TRQ (worse adherence = more severe symptoms), but in most instances was only at a trend level (p > 0.05), with the exception of the correlations between baseline TRQ and MADRS and BPRS, which were positive (r = 0.20 and r = 0.21, respectively) and significant (p ≤ 0.05). CONCLUSIONS: In patients with BD, monitoring increased adherence by 15%. MEMS identified 20% more non-adherence than self-report. Using a standard procedure to identify a single index drug for adherence monitoring may be one way to assess global adherence in patients with BD receiving polypharmacy treatment. Greater BD symptom severity may be a clinical indicator to assess for adherence problems.
Authors: Alessandra M A Nivoli; Francesc Colom; Andrea Murru; Isabella Pacchiarotti; Piero Castro-Loli; Ana González-Pinto; Kostas N Fountoulakis; Eduard Vieta Journal: J Affect Disord Date: 2010-06-09 Impact factor: 4.839
Authors: C E Begley; J F Annegers; A C Swann; C Lewis; S Coan; W B Schnapp; L Bryant-Comstock Journal: Pharmacoeconomics Date: 2001 Impact factor: 4.981
Authors: Lakshmi N Yatham; Sidney H Kennedy; Claire O'Donovan; Sagar Parikh; Glenda MacQueen; Roger McIntyre; Verinder Sharma; Peter Silverstone; Martin Alda; Philippe Baruch; Serge Beaulieu; Andree Daigneault; Roumen Milev; L Trevor Young; Arun Ravindran; Ayal Schaffer; Mary Connolly; Chris P Gorman Journal: Bipolar Disord Date: 2005 Impact factor: 6.744
Authors: John E Zeber; Laurel A Copeland; Chester B Good; Michael J Fine; Mark S Bauer; Amy M Kilbourne Journal: J Affect Disord Date: 2007-09-05 Impact factor: 4.839
Authors: Colin A Depp; David J Moore; Thomas L Patterson; Barry D Lebowitz; Dilip V Jeste Journal: Dialogues Clin Neurosci Date: 2008 Impact factor: 5.986
Authors: Lisa T Eyler; Michelle E Aebi; Rebecca E Daly; Kristen Hansen; Curtis Tatsuoka; Robert C Young; Martha Sajatovic Journal: Am J Geriatr Psychiatry Date: 2019-04-18 Impact factor: 4.105
Authors: Jennifer B Levin; Anna Krivenko; Ashley Bukach; Curtis Tatsuoka; Kristin A Cassidy; Martha Sajatovic Journal: J Nerv Ment Dis Date: 2017-03 Impact factor: 2.254
Authors: Martha Sajatovic; Curtis Tatsuoka; Kristin A Cassidy; Peter J Klein; Edna Fuentes-Casiano; Jamie Cage; Michelle E Aebi; Luis F Ramirez; Carol Blixen; Adam T Perzynski; Mark S Bauer; Steven A Safren; Jennifer B Levin Journal: J Clin Psychiatry Date: 2018-09-25 Impact factor: 4.384
Authors: Jackson M Steinkamp; Nathaniel Goldblatt; Jacob T Borodovsky; Amy LaVertu; Ian M Kronish; Lisa A Marsch; Zev Schuman-Olivier Journal: JMIR Ment Health Date: 2019-03-12
Authors: Tarek A Okasha; Doaa N Radwan; Hussien Elkholy; Heba M F M Hendawy; Eman M M E Shourab; Ramy R A Teama; Ahmed S Abdelgawad Journal: S Afr J Psychiatr Date: 2020-02-10 Impact factor: 1.550